Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28335510 | 0.98 | PKM (0.58) | PKMHSD17B10ALOX15L3MBTL1MEN1 | |
| Hydrochloric Acid SCHEMBL28740356 | 0.96 | PKM (0.57) | PKMHSD17B10ALOX15L3MBTL1MEN1 | |
| Hydrochloric Acid SCHEMBL28553412 | 0.96 | PKM (0.57) | PKMHSD17B10ALOX15L3MBTL1MEN1 | |
| Nitrogen SCHEMBL9116438 | 0.96 | PKM (0.57) | PKMHSD17B10ALOX15L3MBTL1MEN1 | |
| SCHEMBL10244134 | 0.87 | PKM (0.49) | PKMHSD17B10ALOX15L3MBTL1MEN1 | |
| SCHEMBL21893748 | 0.86 | PKM (0.51) | PKMHSD17B10ALOX15L3MBTL1MEN1 | |
| SCHEMBL10424519 | 0.86 | HTR1A (0.59) | HSD17B10L3MBTL1KMT2ARAB9ABRD4 | |
| SCHEMBL6703722 | 0.85 | LMNA (0.48) | PKMHSD17B10ALOX15L3MBTL1MEN1 | |
| SCHEMBL7008376 | 0.84 | SMN1; SMN2 (0.51) | PKMHSD17B10ALOX15L3MBTL1MEN1 | |
| SCHEMBL31256649 | 0.84 | SMN1; SMN2 (0.48) | PKMHSD17B10ALOX15L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024010810-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| CN-114031477-B | Method for reducing amide compounds into amine compounds by cobalt catalysis | 浙江工业大学 | 2023-12-05 | — | — | CN | disclosed |
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| WO-2019136093-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-07-11 | — | — | WO | disclosed |
| US-10308653-B2 | Diazepane derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10035768-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| WO-2018129287-A1 | HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20090062363-A1 | AMIDE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090036506-A1 | 5-Iodotetrazoles | LANXESS DEUTSCHLAND GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036506-A1 | 5-Iodotetrazoles | LANXESS DEUTSCHLAND GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1988076-A1 | AMIDE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-05 | — | — | EP | disclosed |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
| US-20070185130-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ROSKAMP RESEARCH LLC | 2007-08-09 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ALZHEIMER'S INSTITUTE OF AMERICA, INC. | 2007-02-15 | — | — | US | disclosed |
| WO-2005077885-A1 | RUTHENIUM-CATALYZED HYDROAMINATION OF OLEFINS | YALE UNIVERSITY (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | PKM 3896/4885HSD17B10 1632/4885ALOX15 1526/4885 |
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN5A, SCN2A | PKM 3123/4885HSD17B10 3342/4885ALOX15 4214/4885 |
| US-10308653-B2 | Diazepane derivatives and uses thereof | BRDT, BRD4, BAZ2A | PKM 2939/4885HSD17B10 1767/4885ALOX15 3541/4885 |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | PKM 1365/4885HSD17B10 3828/4885ALOX15 4166/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | PKM 1365/4885HSD17B10 3828/4885ALOX15 4166/4885 |
| US-10035768-B2 | C5aR antagonists | C5AR1, C5AR2, C3AR1 | PKM 4678/4885HSD17B10 4597/4885ALOX15 624/4885 |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | MMP8, MMP26, MMP9 | PKM 4479/4885HSD17B10 667/4885ALOX15 733/4885 |
| US-20070185130-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | PKM 1665/4885HSD17B10 2623/4885ALOX15 2899/4885 |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | PKM 1665/4885HSD17B10 2623/4885ALOX15 2899/4885 |
| US-20090036506-A1 | 5-Iodotetrazoles | GPX4, CYP1A1, CYP2E1 | PKM 3903/4885HSD17B10 1398/4885ALOX15 311/4885 |
| US-20090062363-A1 | AMIDE DERIVATIVE OR SALT THEREOF | HTR7, HTR2B, NPSR1 | PKM 4654/4885HSD17B10 1227/4885ALOX15 1251/4885 |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | PKM 1365/4885HSD17B10 3828/4885ALOX15 4166/4885 |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | CDKL2, CDK2, CDKL1 | PKM 879/4885HSD17B10 2726/4885ALOX15 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.